phenytoin has been researched along with tocainide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Brouillette, WJ; Brown, GB; Zha, C | 1 |
| Kwieciński, H; Ostrzycki, A; Ryniewicz, B | 1 |
| Bolton, CF; Hahn, AF; Parkes, AW; Stewart, SA | 1 |
| Podrid, PJ | 1 |
| Keefe, DL; Miura, D; Somberg, JC | 1 |
| Schwarz, JR | 1 |
| Somberg, J | 1 |
| Roden, DM; Siddoway, LA; Woosley, RL | 1 |
| Andersson, KE; Wettrell, G | 1 |
| Huang, SK; Marcus, FI | 1 |
| Di Biase, M; Favale, S; Rizzon, P; Visani, L | 1 |
| Aichele, R; Heller, AH; Paik, H | 1 |
| Doherty, JU; Josephson, ME; Kienzle, MG; Williams, PD; Zygmont, D | 1 |
| Courtney, KR | 1 |
| Rosen, MR; Wit, AL | 1 |
| Block, PJ; Winkle, RA | 1 |
| Cho, YW; Kuemmerle, HP; Singh, BN | 1 |
| Dzimiri, N | 1 |
10 review(s) available for phenytoin and tocainide
| Article | Year |
|---|---|
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Death, Sudden; Disopyramide; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Phenytoin; Procainamide; Quinidine; Random Allocation; Tocainide | 1985 |
The treatment of ventricular rhythm disturbances.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Disopyramide; Electric Countershock; Electric Stimulation; Electrocardiography; Exercise Test; Flecainide; Heart Ventricles; Humans; Lidocaine; Phenytoin; Piperidines; Procainamide; Quinidine; Risk; Tachycardia; Tocainide; United States; Ventricular Fibrillation; Verapamil | 1986 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Bepridil; Bethanidine; Bretylium Tosylate; Disopyramide; Drug Administration Schedule; Encainide; Flecainide; Heart Conduction System; Humans; Imidazoles; Lidocaine; Mexiletine; Moricizine; Myocardial Contraction; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Pyrrolidines; Quinidine; Tocainide; Verapamil | 1985 |
Clinical pharmacology of old and new antiarrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anilides; Anti-Arrhythmia Agents; Benzeneacetamides; Biological Availability; Bretylium Compounds; Disopyramide; Encainide; Flecainide; Humans; Imipramine; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Tocainide | 1985 |
Cardiovascular drugs. I: Antidysrhythmic drugs.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Agents; Disopyramide; Drug Interactions; Humans; Kinetics; Lidocaine; Mexiletine; Phenytoin; Procainamide; Tocainide; Verapamil | 1986 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecainide; Heart Ventricles; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Sotalol; Tocainide; Verapamil | 1986 |
Class 1B agents lidocaine, mexiletine, tocainide, phenytoin.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; Phenytoin; Tocainide | 1987 |
Antiarrhythmic drug therapy for sustained ventricular tachycardia.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benzeneacetamides; Bethanidine; Calcium Channel Blockers; Disopyramide; Drug Therapy, Combination; Electrocardiography; Electrophysiology; Encainide; Heart Ventricles; Humans; Lidocaine; Mexiletine; Phenytoin; Piperidines; Procainamide; Quinidine; Tachycardia; Tocainide | 1984 |
Electropharmacology of antiarrhythmic drugs.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Electric Conductivity; Heart Atria; Heart Ventricles; Humans; Lidocaine; Membrane Potentials; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Procainamide; Propranolol; Purkinje Fibers; Quinidine; Tocainide; Verapamil | 1983 |
Hemodynamic effects of antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Benzeneacetamides; Bretylium Compounds; Calcium Channel Blockers; Disopyramide; Dose-Response Relationship, Drug; Encainide; Flecainide; Hemodynamics; Humans; Lidocaine; Mexiletine; Myocardial Contraction; Phenytoin; Piperidines; Procainamide; Quinidine; Tocainide | 1983 |
2 trial(s) available for phenytoin and tocainide
| Article | Year |
|---|---|
Treatment of myotonia with antiarrhythmic drugs.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Disopyramide; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Mexiletine; Middle Aged; Myotonia; Myotonia Congenita; Myotonic Dystrophy; Neurologic Examination; Phenytoin; Prospective Studies; Single-Blind Method; Tocainide | 1992 |
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Death, Sudden; Disopyramide; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Phenytoin; Procainamide; Quinidine; Random Allocation; Tocainide | 1985 |
12 other study(ies) available for phenytoin and tocainide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
Topics: Ligands; Models, Molecular; Quantitative Structure-Activity Relationship; Voltage-Gated Sodium Channels | 2014 |
Neuromyotonia in hereditary motor neuropathy.
Topics: Adolescent; Anti-Arrhythmia Agents; Carbamazepine; Child; Electromyography; Female; Humans; Lidocaine; Male; Muscles; Myotonia Congenita; Myotonic Dystrophy; Neural Conduction; Neuromuscular Diseases; Pedigree; Peripheral Nerves; Peripheral Nervous System Diseases; Phenytoin; Tocainide | 1991 |
[Membrane currents and action potentials of myelinated nerve fibers and their modification by diphenylhydantoin and tocainide].
Topics: Action Potentials; Animals; In Vitro Techniques; Ion Channels; Lidocaine; Nerve Fibers, Myelinated; Phenytoin; Potassium Channels; Rana esculenta; Rats; Rats, Inbred Strains; Sodium Channels; Tocainide | 1988 |
Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia.
Topics: Animals; Lidocaine; Mice; Mice, Mutant Strains; Myotonia; Phenytoin; Procainamide; Tocainide | 1985 |
Depressant effects of drugs used in myotonia therapy.
Topics: Animals; In Vitro Techniques; Ion Channels; Lidocaine; Mexiletine; Muscle Contraction; Myotonia; Phenytoin; Procainamide; Quinidine; Rana catesbeiana; Tocainide | 1982 |
Clinical pharmacology of antiarrhythmic drugs: a review and overview, part II.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Humans; Kinetics; Lidocaine; Mexiletine; Phenytoin; Procainamide; Propranolol; Tocainide | 1981 |
Effects of procainamide, tocainide and phenytoin on guinea pig cardiac mitochondrial ATPase activity.
Topics: Adenosine Triphosphatases; Animals; Dose-Response Relationship, Drug; Guinea Pigs; Mitochondria, Heart; Phenytoin; Procainamide; Tocainide | 1993 |